Study Identifies How a Long-Linked Gene Variant May Drive Inflammatory Bowel Disease
Inflammatory bowel disease is a group of chronic digestive disorders that has challenged scientists for decades. A new study has now identified how a specific immune system gene variant, long associated with more severe forms of the disease, may contribute to its development.
Researchers from the United Kingdom and Denmark focused on a gene variant known as HLA-DRB1*01:03, which previous genetic studies have consistently linked to inflammatory bowel disease. Until now, however, the biological mechanism explaining how this variant contributes to intestinal inflammation had remained unclear.
How the Gene Variant Contributes to Disease
The researchers analyzed blood samples from approximately 4,900 people with inflammatory bowel disease and around 1,000 individuals without the condition. They searched for autoantibodies that neutralize interleukin-10, an important immune signaling molecule that normally helps suppress excessive inflammation in the intestine.
Autoantibodies against interleukin-10 were detected in approximately 3.5 percent of patients with inflammatory bowel disease but were not found in any of the healthy volunteers. Among patients, these antibodies were present in about 2.5 percent of those with Crohn's disease and 4.4 percent of those with ulcerative colitis.
By comparing genetic data, the researchers identified a strong association between the HLA-DRB1*01:03 variant and the subgroup of patients carrying interleukin-10 autoantibodies. The findings suggest that this genetic variant increases the likelihood that the immune system will mistakenly attack the very molecule responsible for limiting inflammation.
Why the Findings Matter
According to the researchers, the findings help resolve a scientific question that has remained unanswered for approximately 30 years by linking a well-established genetic risk factor to a specific disease mechanism. The study identifies a distinct subgroup of inflammatory bowel disease in which inflammation appears to be driven by an autoimmune response against interleukin-10 rather than by broader immune dysfunction alone.
Inflammatory bowel disease affects millions of people worldwide, and its prevalence has continued to rise across Europe, North America, and many emerging economies. Although only a relatively small proportion of patients appear to belong to this newly identified subgroup, the total number of affected individuals could still be considerable.
The research also demonstrates how studying rare inherited immune disorders can improve understanding of much more common diseases. Earlier investigations of patients with inherited defects affecting interleukin-10 or its receptor helped lay the foundation for identifying the same biological pathway in a broader population of people with inflammatory bowel disease.
Implications for Future Treatments
Current treatments for inflammatory bowel disease primarily aim to reduce inflammation or control symptoms, and many patients ultimately require surgery. Despite advances in therapy, there is still no cure, and some medications become less effective over time or produce significant side effects.
Identifying patients whose disease is driven by an autoimmune response against interleukin-10 could eventually make it possible to provide more targeted treatment at an earlier stage. In the future, clinicians may use antibody testing alongside genetic screening to personalize therapy, reduce unnecessary long-term medication exposure, and potentially lower the risk of severe complications.
The researchers emphasize that further studies will be needed before these findings can be translated into new treatments. Potential future approaches may include restoring interleukin-10 signaling or selectively targeting the harmful autoantibodies. Nevertheless, the study provides a clearer therapeutic target and represents an important step toward more personalized treatment strategies for inflammatory bowel disease.
The findings, published in the New England Journal of Medicine, are expected to contribute to ongoing efforts to better understand the complex genetic and immune mechanisms underlying chronic intestinal inflammation. As this knowledge continues to expand, researchers hope it will ultimately lead to treatments that address the underlying causes of inflammatory bowel disease rather than focusing primarily on long-term symptom management.
